Results 261 to 270 of about 523,497 (297)
Some of the next articles are maybe not open access.
Current Opinion in Hematology, 2020
Purpose of review Myeloid sarcoma; also known as granulocytic sarcoma and chloroma, often occurs concomitantly with AML, and rarely without bone marrow involvement. In this article, we review the recent literature on myeloid sarcoma, focusing on treatment approach for this rare disease, and addressing the prognostic and ...
Omar A, Shahin, Farhad, Ravandi
openaire +2 more sources
Purpose of review Myeloid sarcoma; also known as granulocytic sarcoma and chloroma, often occurs concomitantly with AML, and rarely without bone marrow involvement. In this article, we review the recent literature on myeloid sarcoma, focusing on treatment approach for this rare disease, and addressing the prognostic and ...
Omar A, Shahin, Farhad, Ravandi
openaire +2 more sources
The International Journal of Biochemistry & Cell Biology, 2004
Granulocytes and monocytes, collectively called myeloid cells, are differentiated descendants from common progenitors derived from hematopoietic stem cells in the bone marrow. Commitment to either lineage of myeloid cells is controlled by distinct transcription factors followed by terminal differentiation in response to specific colony-stimulating ...
Hiroshi, Kawamoto, Nagahiro, Minato
openaire +2 more sources
Granulocytes and monocytes, collectively called myeloid cells, are differentiated descendants from common progenitors derived from hematopoietic stem cells in the bone marrow. Commitment to either lineage of myeloid cells is controlled by distinct transcription factors followed by terminal differentiation in response to specific colony-stimulating ...
Hiroshi, Kawamoto, Nagahiro, Minato
openaire +2 more sources
Oncology Research and Treatment, 2019
Hematological malignancies can manifest as extramedullary soft tissue masses in relatively rare cases. The rarity of it causes a diagnostic and therapeutic challenge. One of the rarest manifestations is myeloid sarcoma (MS). MS develops as part of acute myeloid leukemia, myeloproliferative neoplasm, or myelodysplastic syndrome or at relapse, especially
Mohamed, Magdy +5 more
openaire +2 more sources
Hematological malignancies can manifest as extramedullary soft tissue masses in relatively rare cases. The rarity of it causes a diagnostic and therapeutic challenge. One of the rarest manifestations is myeloid sarcoma (MS). MS develops as part of acute myeloid leukemia, myeloproliferative neoplasm, or myelodysplastic syndrome or at relapse, especially
Mohamed, Magdy +5 more
openaire +2 more sources
CD1c(+) myeloid dendritic cells in myeloid neoplasia
Cytometry Part B: Clinical Cytometry, 2015We determined the normal level and phenotype of CD1c(+) myeloid dendritic cells (MDCs) in blood and bone marrow and evaluated the level of CD1c(+) MDCs in 295 myeloid neoplasms. CD1c(+) MDCs were increased above the mean level of non‐neoplastic hospital controls in 18.0% (53/295) of myeloid malignancies, increased three standard deviations above the ...
Howard J, Meyerson +7 more
openaire +2 more sources
Clinics in Laboratory Medicine, 2017
The classification of myeloid neoplasms has undergone major changes and currently relies heavily on genetic abnormalities. Cutaneous manifestations of myeloid neoplasms may be the presenting sign of underlying bone marrow disease. Dermal infiltration by neoplastic cells may occur in otherwise normal skin or in sites of cutaneous inflammation.
openaire +2 more sources
The classification of myeloid neoplasms has undergone major changes and currently relies heavily on genetic abnormalities. Cutaneous manifestations of myeloid neoplasms may be the presenting sign of underlying bone marrow disease. Dermal infiltration by neoplastic cells may occur in otherwise normal skin or in sites of cutaneous inflammation.
openaire +2 more sources
Hematology, 2001
AbstractThrough the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies.
F R, Appelbaum +3 more
openaire +2 more sources
AbstractThrough the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies.
F R, Appelbaum +3 more
openaire +2 more sources
Journal of Leukocyte Biology, 1999
Abstract There is considerable but as yet incomplete evidence for two developmental lineages of dendritic cells: a myeloid lineage shared with phagocytes and a lymphoid lineage shared with T cells. The two corresponding functional states, which may not require the existence of two formal lineages, are that myeloid dendritic cells capture
R M, Steinman, K, Inaba
openaire +2 more sources
Abstract There is considerable but as yet incomplete evidence for two developmental lineages of dendritic cells: a myeloid lineage shared with phagocytes and a lymphoid lineage shared with T cells. The two corresponding functional states, which may not require the existence of two formal lineages, are that myeloid dendritic cells capture
R M, Steinman, K, Inaba
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2009
The evolution of acute myeloid leukemia (AML) classification reflects greater understanding of the AML pathogenesis. The 2008 World Health Organization classification incorporated cytogenetic and molecular genetic findings and introduced important prognostic correlations.
Amy, Heerema-McKenney, Daniel A, Arber
openaire +2 more sources
The evolution of acute myeloid leukemia (AML) classification reflects greater understanding of the AML pathogenesis. The 2008 World Health Organization classification incorporated cytogenetic and molecular genetic findings and introduced important prognostic correlations.
Amy, Heerema-McKenney, Daniel A, Arber
openaire +2 more sources
The Lancet, 2023
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most especially incorporating measurable residual disease ...
Courtney D, DiNardo +3 more
openaire +2 more sources
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most especially incorporating measurable residual disease ...
Courtney D, DiNardo +3 more
openaire +2 more sources